Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: DDD Limited, 94 Rickmansworth Road, Watford, Hertfordshire, WD18 7JJ
Treatment of early stages (prodrome or erythema phase) of recurrent labial herpes simplex infection (cold sores) in immunocompetent adults.
Cutaneous use.
Apply a thin film carefully over the entire cold sore 5 times a day (approximately every 3 hours during waking hours).
Treatment must begin as soon as possible after the first cold sore symptoms or signs appear (pain, burning/itching/tingling or redness) as efficacy has not been demonstrated when the treatment is initiated at the stage of an already developed blister or ulcer.
Treatment should continue until healing has occurred, usually 4 to 6 days, or for a maximum of 10 days.
No special dose recommendation.
The safety and efficacy of Blistex Cold Sore Cream in children aged younger than 12 years have not been established.
No dose adjustments necessary due to negligible topical absorption.
Adverse reactions related to overdose by topical application of Blistex Cold Sore Cream are unlikely because of negligible percutaneous absorption. Similarly, poor oral absorption makes the occurrence of adverse reactions unlikely following ingestion of docosanol.
Shelf life: 3 years.
After first opening the container: 6 months.
Do not store above 25°C.
Epoxy-lined aluminium tubes closed with a polyethylene screw cap.
Pack size: 2 g
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
